Argos Therapeutics, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ARGS’ earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Argos Therapeutics could be a solid choice for investors.
Current Quarter Estimates for ARGS
In the past 30 days, 3 estimates have gone higher for Argos Therapeutics with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 37 cents a share 30 days ago, to a loss of 29 cents today, a move of 21.6%.
Current Year Estimates for ARGS
Meanwhile, Argos Therapeutics’ current year figures are also looking quite promising, with 36 estimates moving higher in the past month, compared to 1 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.56 per share 30 days ago to a loss of $1.39 per share today, an increase of 10.9%.
Bottom Line
The stock has also started to move higher lately, adding 6.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Image: Bigstock
Why Argos Therapeutics (ARGS) Could Be Positioned for a Surge
Argos Therapeutics, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ARGS’ earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Argos Therapeutics could be a solid choice for investors.
Current Quarter Estimates for ARGS
In the past 30 days, 3 estimates have gone higher for Argos Therapeutics with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 37 cents a share 30 days ago, to a loss of 29 cents today, a move of 21.6%.
Current Year Estimates for ARGS
Meanwhile, Argos Therapeutics’ current year figures are also looking quite promising, with 36 estimates moving higher in the past month, compared to 1 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.56 per share 30 days ago to a loss of $1.39 per share today, an increase of 10.9%.
ARGOS THERAPEUT Price and Consensus
ARGOS THERAPEUT Price and Consensus | ARGOS THERAPEUT Quote
Bottom Line
The stock has also started to move higher lately, adding 6.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>